Investor Relations
ir@vesaliuslabs.comVesalius IR
Verified investor inquiries — two business day response.
Securities notice · Vesalius Longevity Labs is not yet a reporting issuer. The proposed reverse takeover transaction is subject to regulatory and shareholder approvals. Nothing on this site constitutes an offer to sell or solicitation to buy securities.
FAQ, email updates, and direct IR contacts.
The most common investor questions, a single-click subscription to material announcements, and a direct line to the IR team.
Investor FAQ
The questions analysts and allocators ask most.
If your question isn’t here, please email ir@vesaliuslabs.com and we will route it to the right person.
What is Vesalius’s listing path?
Vesalius Longevity Labs is the subject of a reverse takeover transaction. A binding letter of intent was announced in March 2025 and superseded by a definitive agreement on June 23, 2025. Closing is subject to customary regulatory and shareholder approvals.
Where will the combined company trade after close?
On close, the resulting issuer is expected to be renamed Vesalius Longevity Labs Inc. and to trade under the ticker CSE: VLAB, with trading expected in Q3 2026 subject to customary approvals.
Where can I find regulatory filings?
All public filings are available on SEDAR+ (the Canadian System for Electronic Document Analysis and Retrieval). Vesalius does not currently file with the U.S. SEC. If you are a U.S. investor, please consult your own advisor before relying on any of the information published here.
Does Vesalius offer securities directly through this website?
No. Nothing on this website constitutes an offer to sell or a solicitation of an offer to buy any security. All securities-related transactions are conducted through the resulting issuer’s public listing.
Who do I contact for investor relations?
Email ir@vesaliuslabs.com. We respond to verified investor inquiries within two business days. For media inquiries, please use media@vesaliuslabs.com instead.
Are forward-looking statements covered by safe harbor?
Information on this site may include forward-looking statements within the meaning of applicable Canadian securities laws. These statements are based on current expectations and are subject to risks and uncertainties. Please see our Forward-Looking Statements page for the full cautionary note.
Talk to the IR team.
Media
media@vesaliuslabs.comVesalius Press
Press, analyst, and editorial inquiries.
Vesalius IR does not provide investment advice. Nothing on this site constitutes an offer to sell or a solicitation of an offer to buy any security. See the Forward- Looking Statements page for the full cautionary note.